Journal of Hypertension

Skip Navigation LinksHome > January 2012 - Volume 30 - Issue 1 > Use of aliskiren in a ‘real-life’ model of hypertension mana...
Journal of Hypertension:
doi: 10.1097/HJH.0b013e32834e1c66
Original papers: Therapeutics aspects

Use of aliskiren in a ‘real-life’ model of hypertension management: analysis of national Web-based drug-monitoring system in Italy

Volpe, Massimoa,b; Tocci, Giulianoa,b; Bianchini, Francescac; De Rosa, Marisad; Fedozzi, Elisabettad; Covezzoli, Annad; Maggioni, Aldo P.c; AIFA Drug Monitoring Program: Aliskiren Registry

Supplemental Author Material


The authors have noted the following required corrections to their article [1].

One page 197, 2nd column, 3rd paragraph, the frequency of prescription for CCBs was 54.9% and not 48.1%.

On page 198, 2nd paragraph of the section “Blood pressure levels during follow-up period” the change in prevalence of hypertensive outpatients achieving the recommended SBP targets patients from 1-month clinical data was “(from 11.9 to 30.0%; P < 0.001)” and not “(from 11.5 to 29.9%; P < 0.001)”.

On page 198, 4th line of the 2nd column the percentage value should have been 26.5% and not -(minus) 26.5%.

On page 198, in the last sentence of the section “Safety and tolerability” the percentage of patients that discontinued the drug treatment at months 1 and 6 of follow-up was 1.7 and 1.3%, respectively, and not 1.4 and 0.9%, respectively. The data was also from the supplementary data in Figure S3 and not Table S4 as indicated.

Journal of Hypertension. 30(4):836, April 2012.

Collapse Box


Introduction: In Italy, prescriptions of the direct renin inhibitor aliskiren (aliskiren) to high-risk hypertensive patients must be electronically filled by specialized physicians only when at least two antihypertensive drug classes (independently of the dosages), fails to normalize blood pressure (BP) levels.

Aim: To analyze the effects of the addition of aliskiren 150–300 mg daily to antihypertensive therapy in a population of high cardiovascular risk hypertensive patients with uncontrolled BP levels.

Methods: Clinical data were derived from patients included in the national Web-based drug-monitoring system. Follow-up visits were required for measuring BP levels, and collecting data on drug safety and tolerability.

Results: Between March 2009 and February 2010, aliskiren was prescribed by 6464 specialized physicians to 11 511 treated, uncontrolled hypertensive patients (47.6% women, aged 68.0 ± 11.1 years, BMI 28.4 ± 4.9 kg/m2) with organ damage or comorbidities. During 6-month observation, only a few drug-related side-effects were reported (n = 33). At the entry and 1-month follow-up visits (n = 8197; 70.6%), BP levels were 158.9 ± 16.8 and 142.1 ± 15.2 mmHg for SBP and 90.8 ± 9.6 and 83.1 ± 8.5 mmHg for DBP, respectively. At 6-month (n = 4907; 42.3%), SBP and DBP levels were 137.9 ± 13.9 and 81.3 ± 8.0 mmHg, respectively. A consistent reduction in the use of all classes of concomitant antihypertensive drugs was recorded.

Conclusion: Although data derived from national registries need to be interpreted with caution, the Italian Web-based drug-monitoring system provided information on ‘real-life’ use of aliskiren in hypertension. In this uncontrolled, high-risk treated hypertensive population, SBP and DBP levels recorded during treatment with aliskiren were consistently lower than those recorded at entry visits in a context of a very low rate of reported side-effects.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.